Health
Animal data supports efficacy of baricitinib vs SARS-COV-2 – News-Medical.Net
The high burden of disease caused by the COVID-19 pandemic has led to much research on effective ways to mitigate the health, social, and economic impact of the spread of the infection. A recent study published on the preprint server bioRxiv* in September 202…
The high burden of disease caused by the COVID-19 pandemic has led to much research on effective ways to mitigate the health, social, and economic impact of the spread of the infection. A recent study published on the preprint server bioRxiv* in September 2020 reports on the characteristics of the drug baricitinib when used as monotherapy to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Inflammatory Responses in COVID-19
Severe COVID-19 is associated with high fever, non-…
-
General15 hours agoAbattoir worker in serious condition after workplace accident in Echuca
-
Noosa News23 hours agoBroncos media boss Melissa Mallet to face court over alleged drink-driving crash
-
General20 hours ago‘Sovereign citizens’ sentenced to prison term in Western Australia for defiance of court order
-
General15 hours agoWoman who reported NSW MP Gareth Ward’s alleged sex crimes cross-examined